Skip Navigational Links
LISTSERV email list manager
LISTSERV - LISTSERV.ICORS.ORG
LISTSERV Menu
Log In
Log In
LISTSERV 17.5 Help - IRIS Archives
LISTSERV Archives
LISTSERV Archives
Search Archives
Search Archives
Register
Register
Log In
Log In

IRIS Archives

Information and Referral and Internet Sightings

IRIS@LISTSERV.ICORS.ORG
Menu
LISTSERV Archives LISTSERV Archives
IRIS Home IRIS Home
Log In Log In
Register Register
Subscribe or Unsubscribe Subscribe or Unsubscribe
Search Archives Search Archives
Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
news byte: FDA Conditionally Approves Risperdal for Children
From:
Sylvia Caras <[log in to unmask]>
Reply To:
[log in to unmask]
Date:
Mon, 25 Jun 2007 10:31:27 -0700
Content-Type:
text/plain
Parts/Attachments:
text/plain (9 lines) 
Johnson & Johnson on Thursday said U.S. regulators have given 
conditional approval for use of its drug Risperdal as a treatment for 
adolescents with schizophrenia and children and adolescents in the 
manic phase of bipolar disorder.



Powered by LSoft's LISTSERV(R) list management software

ATOM RSS1 RSS2

LISTSERV.ICORS.ORG CataList Email List Search Powered by LISTSERV